Prostate cancer is the most common cancer affecting men in the United States, with an estimated 238 590 new cases and 29 270 deaths in 2013 (1) . Clinically localized and locally advanced prostate cancer comprise more than 80% of all newly diagnosed cases (1) . Radical prostatectomy (RP), external beam radiation therapy (EBRT), and prostate interstitial brachytherapy (PI) are all considered definitive treatment options for these patients, with 5-year relative survival rates approaching 100% (1) . Ionizing radiation is a known carcinogen. Over the past two decades, several single registry (2) (3) (4) (5) (6) (7) (8) and Surveillance, Epidemiology, and End Results (SEER)-based studies (9-13) have reported variably increased risk of secondary hematological malignancies, mostly leukemias and lymphomas (9) (10) (11) 14, 15) , after radiation to the prostate, particularly in long-term survivors.
Myelodysplastic syndromes (MDS), a myeloid malignancy, is the most common bone marrow failure condition in the United States, with an age-adjusted incidence rate (AAIR) of 4.4 per 100 000 persons (16) . MDS is a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to peripheral cytopenias and their related complications, with an increased risk of progression to acute myeloid leukemia. Although the majority of MDS cases arise de novo, approximately 14% are defined as therapy-related MDS (t-MDS) (17) , occurring on average 5 to 7 years after treatment with cytotoxic chemotherapy, radiation, or both. Exposure to ionizing radiation has been linked to subsequent development of MDS in several cancer cohorts (18) (19) (20) , but the risk of MDS in radiation-treated prostate cancer patients remains unclear.
Delivery of external beam radiation to the prostate results in inadvertent irradiation of the surrounding pelvic bones, estimated to contain more than 50% of the total body reserve of active bone marrow mass (21, 22) . With PI, the potential effect of radiation on bone marrow is unclear. Recent evidence of circulating bone marrow-resident hematopoietic stem cell trafficking through extramedullary sites and homing back to the bone marrow (23) has led to the hypothesis that these bone marrow-resident hematopoietic stem cells are exposed to radiation from implanted [ 125 I] iodine seeds as they pass through the prostate. Considering that prostate cancer patients constitute the second largest group of radiationtreated cancer patients in the United States (24) and the likelihood of exposure of a large volume of active marrow during EBRT as well as the putative mutagenic effects on circulating bone marrowresident hematopoietic stem cells from implanted 125 I seeds, there remains a concern for an increased risk of MDS in this large and growing population of cancer survivors.
We evaluated this risk of developing MDS in a contemporaneous cohort of locoregional prostate cancer patients definitively treated with different radiation modalities and compared it with a surgical cohort and with rates in state and national registries.
Methods

Data Source
Patient characteristics and treatment information were collected from three independent, prospectively maintained databases at Cleveland Clinic-prostate surgery, prostate radiation, and MDS (Table 1 ). National and state AAIR for MDS were collected from SEER 17 (2001-2004 ) and the Ohio Cancer Incidence Surveillance System (OCISS) registry, respectively. The study was approved by the Cleveland Clinic Institutional Review Board.
Study Cohort
The study cohort included 10 924 patients with histopathologically confirmed locoregional prostate adenocarcinoma (clinical stage T1, T2, and T3) newly diagnosed at Cleveland Clinic between January 1986 and July 2011 who underwent definitive treatment with either RP or radiotherapy with EBRT or PI ( Table 2) . Eighteen percent of patients received neoadjuvant androgen deprivation therapy (ADT), 19% of whom received ADT for more than 6 months. No RP patient received adjuvant radiation. Patients with disease recurrence treated with either salvage radiotherapy or surgery were excluded from the study. None of the patients had a history of any cancer before the diagnosis of prostate cancer or in the period between treatment of prostate cancer and the diagnosis of MDS. There was no documented history of prior exposure to cytotoxic chemotherapy for any indication or use of radiotherapy for any condition other than prostate cancer.
Collected patient-specific information included age, race, place of residence, pretreatment prostate-specific antigen levels, Gleason sum, clinical stage using the 1997 American Joint Committee on Cancer classification (25) , prostate cancer risk stratification (26) , use of ADT, prostate-specific antigen (PSA) frequency (number of PSA examinations per year), duration of follow-up, date of MDS diagnosis, and cause of death. Number of PSA examinations every year served as a surrogate indicator for frequency of follow-up. For the subset of 6231 prostate cancer patients diagnosed between 1996 and 2011, additional information was collected on Charlson comorbidity scores (27) , body mass index, and smoking status (Supplementary Table 1, available  online) .
Treatment Details
Patients receiving EBRT and PI followed general treatment planning guidelines that have been previously described (28) (29) (30) . Different radiotherapy modalities were used for treating prostate cancer at Cleveland Clinic from 1986 to 2011, reflecting nationwide adoption of newer radiation technologies with time (Supplementary Figure 1A , available online). Since 1998, intensity modulated radiation treatment has been the EBRT technique of choice (Supplementary Figure 1B, available online) . The median radiation dose delivered through the EBRT approach (all modalities included) was 78 Gray (Gy; range = 59.4-81.5) at 2 Gy per fraction. The PI program began in 1996 and has been the preferred radiation modality since 2002. All PI patients were treated with 144 Gy using 125 I. Two patients who received both EBRT and PI were excluded from this study.
Identification and Selection of MDS Case Patients
As shown in Figure 1 , prostate surgery and radiation databases were initially searched to extract information on patients with MDS using the eResearch methodology. The final extracted cohort of MDS patients from these databases was then cross-referenced with the MDS database to confirm case patients, identify missing case patients, and establish the earliest date of MDS diagnosis. Because of changes in MDS nomenclature (31, 32) and disease coding (33) over the period 1986 to 2011, we established different levels of evidence to establish diagnostic certainty for MDS cases before study inclusion (Table 3) . Only those patients with definite and probable level of diagnostic certainty were included. MDS subtypes were classified according to the World Health Organization classification (32) . Cytogenetic risk groups were assigned as per the International Prognostic Scoring System (35) when available.
Statistical Analysis
Comparisons of pretreatment factors among the three treatment groups were conducted using analysis of variance or χ 2 tests. The Kruskal-Wallis test was used to compare differences in time to event among the MDS patients in the three treatment groups. Censoring occurred at development of MDS, death, or date of last encounter, whichever occurred first. Overall survival rates were compared with the log-rank test. Because of the low event rate vs the potential for patients to have died before developing MDS, a competing risk regression analysis was performed with death from all causes treated as a competing event (36) . The final multivariable model was built using the forward, stepwise procedure. Factors with a P value less than .05 (two-sided test) in univariable analyses were included in multivariable analyses that incorporated differences in duration of follow-up with the development of MDS as the time-dependent endpoint. Variables having a P value of less than .05 remained in the final model. The combined effects of age and body mass index (both known risk factors for MDS) with individual treatment arms (EBRT vs RP, PI vs RP, and PI vs EBRT) were assessed to quantify and compare the risk of MDS across cohorts. Cumulative incidence rates of MDS were calculated, and comparisons among the three treatment groups were made using Gray's test (37) . The competing risk regression analysis and the cumulative incidence rate comparisons were performed using R version 2.13.0 (The R Foundation, morphologic reassessment by hematopathologists before inclusion. The clinical information of all MDS patients included in this study was personally reviewed by two investigators, M. Sekeres and S. Mukherjee. ‡ The prostate surgery (RP) and prostate radiation (RT) databases together comprise the prostate cancer database, which is under a single institutional review board. Because of the size of the data and the differences in the research structure for RP and RT, RP and RT databases are maintained separately by their respective departments. Vienna, Austria). All other statistical analyses were done using SAS version 9.2 (SAS Institute, Cary, NC).
To determine any excess risk of MDS in the Cleveland Clinic prostate cancer cohort, we compared the calculated AAIR of MDS in our group with population rates abstracted from national (SEER 17) and state (OCISS) registries. Although both SEER and OCISS report on radiation treatment, these registries do not stratify radiation treatment by cancer type. Because of this treatment reporting limitation, we did a crude comparison of radiation-related MDS rates in our cohort (prostate cancer patients) to SEER and OCISS rates (inclusive of all de novo as well as all secondary MDS cases arising subsequent to any antecedent malignancy).
results
Demographic and clinical characteristics of 10 924 prostate cancer patients by treatment modality are shown in Table 2 . The median age at the time of prostate cancer treatment for the entire cohort was 64 years (range = 37-88) and differed among treatment groups: 69 years for patients receiving EBRT, 67 years for PI, and 60 years for RP patients (P < .001). Of 10 924 patients, 5119 (47%) received radiation (n = 2183 [43%] in the EBRT group and n = 2936 [57%] in the PI group) and 5805 (53%) were treated with RP. Of all the EBRT modalities used, 521 (24%) patients received four-field radiation, 469 (21%) patients underwent three-dimensional conformal radiotherapy, and 1193 (55%) patients received intensity modulated radiation treatment. The EBRT arm had the highest proportion of patients with clinical stage T2b/2c or T3 prostate cancer (25.5%), Gleason sum greater than 8 (16.8%), the highest median pretreatment prostate-specific antigen levels (9.1 ng/mL), and the highest percentage receiving ADT (46%). The median follow-up for all patients after prostatic intervention was 3.0 years: 6.8 years in the EBRT group, 2.5 years in the PI group, and 1.9 years in the surgery group (P < .001) ( Table 2 ).
In the entire cohort, 31 patients developed MDS: 16 in the EBRT group, nine in the PI group, and six in the surgery group ( Table 2 ). The median age at MDS diagnosis was not statistically significantly different among the treatment groups. The median time to develop MDS was 8.9 years (range = 0.9-20.2): 9.1 for EBRT, 8.2 for PI, and 13.0 for RP patients (P = .05). The cumulative risk for developing MDS increased with duration of followup. The 10-year cumulative incidence rate was 0.7% for EBRT vs 1.8% for PI vs 0.2% for RP (Figure 2 ). The distribution of MDS subtypes is shown in Table 4 . International Prognostic Scoring System cytogenetic risk classification was as follows: good risk (n = 14), intermediate risk (n = 5), poor risk (n = 4) and unknown (n = 8).
In the competing risk regression univariate analysis, those with advanced age (hazard ratio [HR] = 1.14; 95% confidence interval [CI] = 1.09 to 1.20; P < .001) and those treated with radiation (HR = 3.44; 95% CI = 1.41 to 8.37; P = .007) were statistically significantly more likely to develop MDS (Table 5 ). The association with radiation remained statistically significant whether patients received EBRT (HR = 2.82; 95% CI = 1.08 to 7.38; P = .03) or PI . ‡ P value from Kruskal-Wallis. § P value from log-rank test.
|| EBRT modalities include four-field, three-dimensional conformational radiation, and intensity modulated radiation treatment. ¶ Race was self-identified.
# State of residence was derived from patient's postal address at the time of first clinic visit.
** Gleason sum is determined by adding the Gleason grade (1-5) of the two most predominant histologies. † † Prostate cancer risk stratification based on iPSA, clinical stage, and Gleason score. ‡ ‡ D90 (the dose delivered to 90% of the prostate) used to assess implant quality is a measurement independent of isotope used and treatment intention. § § Number of PSA examinations per year.
|||| Breakdown of MDS cases by type of EBRT modality: 6 (37.5%) had four-field, 3 (18.75%) had three-dimensional conformational radiation, and 7 (43.75%) had intensity modulated radiation treatment. ¶ ¶ Crude incidence rate was calculated as the total number of patients divided by person-years accumulated and reported as per 100 000 person-years. (HR = 5.65; 95% CI = 2.03 to 15.71; P < .001). In multivariable analyses adjusting for age, use of radiation, type of radiation modality, and body mass index (Table 5 : models 1 and 2 performed for years 1986-2011; models 3 and 4 for years 1996-2011; models 2 and 4 grouping radiation-treated patients together; models 1 and 3 analyzing type of radiation therapy), only advanced age remained statistically significantly associated with MDS development (HR = 1.13; 95% CI = 1.06 to 1.19; P < .001). Radiation exposure did not increase the risk for MDS (HR = 1.63; 95% CI = 0.59 to 4.53; P = .35). The risk of MDS was slightly increased in PI-treated patients but did not reach statistical significance (P = .08). For the 1996 to 2011 cohort, age and body mass index were statistically significant risk factors for MDS development in multivariable analysis but radiation was not. Table 6 displays the AAIR of MDS in our cohort and two population registries (SEER 17 and OCISS). When compared with the SEER 17 registry, the AAIR for MDS in our prostate cancer population was lower when grouped as a cohort (all treatment modalities combined) or stratified by treatment intervention except for EBRT-treated patients aged between 70 and 79 years. Our AAIR was higher than that reported in the Ohio registry across all treatment cohorts for patients aged 70 years or older.
Discussion
Classification of MDS as being therapy related are functional and based solely on a prior intervention, such as chemotherapy or radiation therapy, having a temporal possibility of causing MDS. This retrospective cohort study did not show an excess risk of MDS in prostate cancer patients definitively treated with radiation when compared with patients treated solely with radical prostatectomy in multivariable analyses accounting for competing risks of death with MDS as a time-dependent endpoint. No increase in MDS incidence was seen in any of the treatment groups when compared with the general population (SEER 17 and OCISS). Although 
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Cases excluded from surgical cohort MDS diagnosed before prostate cancer (n = 3) Clinically documented MDS but normal bone marrow examination (n = 3) Dysplastic marrow changes seen in association with bone marrow involvement by other conditions (n = 3) Prior radiation or cytotoxic chemotherapy for malignancies excluding prostate cancer (n = 4) The clinical rules are then translated into technological queries to extract the data. A team review of the final rule and query is completed before the initial release of the rule into the production system. Additional logic is applied to diagnosis in that to be included in the cohort; the patient must have at least two entries for a specific time period for the study. The requirement of two diagnosis entries can be satisfied by any combination of entries in the problem list, encounter, and/or medical history or can be at least two entries for the specific diagnosis on different encounter dates. Clinical rules are also subject to standardized data governance in that if a clinical rule was developed and has not been reviewed in 1 year or longer, the rule must be reviewed before it can be applied to a study. This review ensures that the rules being applied to studies are the most accurate, comprehensive, and up-to-date definition available for the specific clinical concept. Before the resulting dataset is released to the principal investigator and research team, a review of random patients listed in the results is conducted by eResearch. Patient medical record numbers are used to locate the patient's chart through EPIC to verify that the results from the backend system extract are in agreement with the patient record in EPIC. MDS = myelodysplastic syndromes; EBRT = external beam radiation therapy; PI = prostate interstitial brachytherapy; RP = radical prostatectomy.
treatment reporting limitations do not allow direct comparison with population registries, the low MDS rates in our cohort would be consistent with t-MDS rates extrapolated from these registries (17, 38, 39) . The question of secondary malignancy occurrence as a function of type of radiation modality (10, 11, 15) is an important one in our cohort because patients were exposed to different radiation modalities depending on the time period they received prostate intervention. After adjusting for the year of treatment, patients treated with any EBRT modality or PI did not appear to have an excess risk of MDS. Although long-term use of ADT could have deleterious effects on bone marrow, no such association was reported in a recent Kaiser Permanente study (40) . Moreover, in more than 75% of patients included herein, ADT use was short (<6 months). The majority of evidence implicating radiation exposure to an increased risk of t-MDS/acute myeloid leukemia comes from retrospective cohort studies in non-Hodgkin's lymphoma (18), Hodgkin's lymphoma (19) , and breast cancer patients (20, 41, 42) treated with various treatment modalities, in which the increased risk was specific for patients treated with alkylating chemotherapy either alone or in combination with radiation (18) . In non-Hodgkin's lymphoma (19, (43) (44) (45) ) and Hodgkin's lymphoma patients (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) treated with radiation alone, no increase in risk of t-MDS/ acute myeloid leukemia was observed, similar to our findings. However, the risk did appear to be increased in select radiationtreated non-Hodgkin's lymphoma cohorts in whom total lymph node radiation (44) or total body irradiation (62,63) was used. The risk is highest in patients with relapsed or refractory non-Hodgkin's lymphoma treated with high-dose chemotherapy and total body irradiation as a preparative regimen before autologous stem cell transplant with a reported cumulative incidence rate of t-MDS/ acute myeloid leukemia exceeding 10% at 10 years of follow-up (18) . However, comparisons of t-MDS risk across different studies is challenging for several reasons, including differences in patient populations and interstudy variabilities in treatment-related risk exposures, such as use of combined modality regimens, type of chemotherapy (alkylating agents, topoisomerase inhibitors), cumulative chemotherapy dose, dose and volume of radiation, use of total body irradiation in pretransplant conditioning regimen, and risk assessment methodology.
In addition to disease and treatment reporting limitations, one of the major challenges in estimating the true risk of t-MDS from population registries has been misclassification bias, mostly due to diagnostic complexities unique to MDS. In one registry-based Table 3 . Criteria levels for myelodysplastic syndromes diagnosis in prostate cancer patients*
Level of diagnostic certainty
Histopathological, cytogenetic, laboratory, and medical documentation criteria
No. of cases
Definite* (a) Case confirmation based on minimal diagnostic criteria, which required presence of both "prerequisite criteria" and at least one of three decisive criteria or presence of both prerequisite criteria and co-criteria when none of the decisive criteria are present Prerequisite criteria: Marked cytopenia (hemoglobin < 11 g/dL, ANC < 1.5 x 10 9 /L, or platelets < 100 x 10 9 /L) in at least one cell lineage for ≥6 months and exclusion of all other hematopoietic or nonhematopoietic disorders as causes for dysplasia or cytopenia Marked, persistent (≥6 months) cytopenia in one or more cell lineages, dysplasia in bone marrow not reaching the morphologic criterion of >10% (or presence of dysplasia in peripheral blood) with or without presence of MDS-associated chromosomal aberrations (metaphase cytogenetics/ FISH on bone marrow or peripheral blood) in absence of minimal criteria for MDS and not explained by any other causes. Exhaustive evaluation for secondary etiologies including nutritional deficiencies, heavy metal screen, medications, autoimmune conditions, gastrointestinal bleeding, splenomegaly/hypersplenism, chronic renal insufficiency, endocrinopathies, paraproteinemia, PNH and infections (notably HIV, HCV, CMV, EBV, and others) in these cases was unremarkable study, 12% of 24 798 MDS patients did not have any morphological confirmation and 56% failed to meet the diagnostic threshold for MDS (38) . A glimpse of this bias can be seen in our series, where of the original 59 MDS patients identified, only 31 (53%) met the minimal diagnostic criteria for MDS. To ensure capturing MDS patients that are truly reflective of those considered clinically relevant, we defined the category "evolving MDS" based on strict exclusion criteria. This category might well represent idiopathic cytopenia of undetermined significance or idiopathic dysplasia of uncertain significance (64) , recently recognized bone marrow failure entities that have previously not been associated with radiation exposure. This study has several limitations. Like other observational studies of treatment effects, selection bias, confounding by indication, and loss to follow-up need to be considered while interpreting these results. Duration of follow-up is an important criterion of MDS risk estimation because of the low event rate and the long latency period for MDS development (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) . The relatively short median follow up for our cohort (approximately 3 years) is because of more patients being treated in the later years of the study period: 2.2% from 1986 to 1990; 7.6% from 1991 to 1995; 18.6% from 1996 to 2000; 30.4% from 2001 to 2005; and 41.1% from 2006 to 2011. For the MDS and radiation therapy databases, follow-up was thorough mainly because the nature of these treatment modalities selects for patients deriving primarily from Northeast Ohio and surrounding regions who continue to receive care at our institution. Although RP patients had less intensive follow-up (median of 2 years), this would have resulted in lower rates of MDS ascertainment, bolstering the finding that radiation therapy does not increase MDS rates.
Although EBRT-treated patients who had the highest volume of radiation exposure (mainly from intensity modulated radiation treatment) and were followed for the longest period (median of approximately 7 years) had no increase in MDS rates, a small albeit, non-statistically significant risk of MDS in the PI group was observed within 2.5 years of intervention. Although this raises concern for the PI group, biological data suggest otherwise. Considering the rapid decay in radioactivity of the implanted 125 I seeds, it is physically improbable for radiation scatter to reach pelvic marrow in doses sufficient to exert carcinogenic effect. Even if the hypothesis of radiotoxicity to the circulating bone marrow-resident hematopoietic stem cells from PI is considered, the * Age-adjusted incidence rate (AAIR) is the number of cases for specific age group divided by the estimated population for that specific age group multipled by 100 000 to obtain the crude incidence rate, which is then multiplied by appropriate population weight of the particular age group determined from the US 2000 standard population. For all cohorts, the AAIR rates are expressed as number of events (MDS cases) per 100 000 people. Age adjusted rate was calculated as a weighted average of the age-specific rates, where the weights were the proportions of persons in the corresponding age groups of a standard population, which in this case was the Surveillance, Epidemiology and End Result US 2000 standard population (19 age groups, Census P25-1130). EBRT = external beam radiotherapy; MDS = myelodysplastic syndromes; PI = Prostate Interstitial brachytherapy; RP = radical prostatectomy; SEER = Surveillance, Epidemiology and End Result. † AAIR for SEER 17 geographic areas was obtained from time it would take for these affected cells to reach a mutagenic threshold for MDS initiation would be decades, as seen in Japanese atomic bomb survivors (65) . For radiation-treated prostate cancer patients in particular, estimation of the relatively short-term risk of developing MDS is clinically more meaningful than gauging the long-term risk for several reasons. By the time patients in our cohort developed MDS, they were in their eighth decade of life. This advanced age has treatment implications. With advancing age, the MDS population is more vulnerable to toxicities of available therapies because of substantial existing comorbidities (66) , and thus this population is less likely to be subject to intervention. Being able to detect this secondary complication earlier when these patients are in a better physical state allows for therapies, including bone marrow transplantation. Moreover, prolonged follow-up in our cohort would likely be truncated by competing intercurrent illness and, importantly, expected lifespan. Finally, with an aging bone marrow compartment, the finite number of stem cells is more susceptible to damage, arguing for a shorter time to develop MDS than in historically younger secondary MDS populations (19, (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) . The strengths of this study include a large population with single-agent exposure that obviates the confounding effect of other interventions, rigorous diagnostic criteria for case ascertainment, competing risk analysis, and detailed patient, disease, and treatment-related information not available through cancer registries.
In conclusion, with relatively short follow-up, radiation therapy for prostate cancer does not appear to increase the risk of subsequent development of MDS. These findings should be reassuring to both patients and physicians who harbor concerns about the risk of radiation-induced MDS, especially in a growing population of radiation-treated long-term prostate cancer survivors. 
